Consumer Genomics Key Players and Development Strategy

Learn About the Major Players in the Consumer Genomics Market

• Nucleus Genomics
• Illumina, Inc.
• SOFiA Genetics
• Metabolomic Discoveries GmbH
• Amgen, Inc.
• MyHeritage Ltd.
• Xcode Life
• Positive Biosciences, Ltd
• Veritas
• Gene by Gene, Ltd. (FamilyTree DNA)
• Mapmygenome
• Diagnomics, Inc.
• QuickCheck Health
• SomaLogic, Inc.
• Helix OpCo LLC
• Color Health, Inc
• Futura Genetics
• Inui Health (formerly Scanadu)
• Pathway Genomics
• Ancestry
• 23andMe, Inc.
• Myriad Genetics, Inc
• Toolbox Genomics
• AgeCurve
• Biomeb

Industry at a Glance

The consumer genomics market consists of two segments: consumer-driven genetic testing, which is genetic testing ordered by a health care provider in response to an informed patient request, and direct-to-consumer applications, which are genetic tests obtained directly from a commercial company without the involvement of a health care provider. Due to the possibility of consumer misinterpretation, conversations on the necessity to demonstrate clinical and analytical validity as well as clinical utility have arisen as consumer genomics has become more and more integrated with clinical applications. Practitioners have faced obstacles in terms of education and training because of clinical preparedness and interest in this information. Concurrently, the consumer genomics market has surfaced as a potentially inventive domain for contemplating health literacy and enlisting individuals in their own health and medical care.

Market Growth

The global consumer genomics market size is expected to grow from USD 2.45 billion in 2025 to USD 18.04 billion by 2034, with a CAGR of 24.85% throughout the forecast period from 2025 to 2034.

Regional Companies Insights

Canada

• In March 2024, one of the top personal genomics businesses in India, Xcode Life, announced the release of their brand-new "Genes and Caffeine" test. Since every person has a different connection with coffee, this test has been created with that in mind. It offers insights into how a person's genes affect their body's response to caffeine, delving further into the realm of caffeine than the typical "one-size-fits-all" advice. India's most thorough gene nutrition test, covering almost 50 nutritional factors, is provided by Xcode Life.

India

• In January 2025, India launched the “Genome India” database for researchers across the world, and it is housed at the Indian Biological Data Center (IBDC) in Faridabad, Haryana. The database is a compilation of 10,000 human genomes from India, representing 83 population groups, or about 2% of the country’s 4,600 population.

UK

• The Genetic Disease Alliance organization of the UK reported that there are 3.5 million individuals living with a rare disorder. 1 in 17 people are affected by a rare condition at some point in their lives. Additionally, around 6,000 children are born with a genetic disorder annually in the UK.

Germany

• It is estimated that about 4 million people are living with a rare disease in Germany, out of the 30 million people in Europe. The German government and the Helmholtz Association announced an investment of €128 million in the NAKO study, Germany’s largest health study, for the next five years (2023-2028). The study aims to investigate chronic diseases, like cancer, diabetes, and cardiovascular diseases to improve their prevention, early diagnosis, and treatment.

Recent Developments in the Consumer Genomics Market

1. Nucleus Genomics

• Headquarters: New York, U.S., North America

• Date: March 2024

• Overview: Nucleus Genomics, a company specializing in next-generation genetic testing and analysis, launched its new DNA analysis product.

• Key Features:

  • Allows consumers who have previously taken microarray genetic tests with other companies to upload their DNA data onto Nucleus’ platform.

  • Provides insights into genetic susceptibility to various diseases, including breast cancer and type 2 diabetes.

  • Incorporates lifestyle and personal parameters such as age, blood pressure, cholesterol, and BMI to offer personalized risk assessments.

• Goal: To make the benefits of personalized healthcare accessible to everyone through advanced genetic analysis.

2. SOPHiA GENETICS

• Headquarters: Switzerland, Europe

• Date: May 2024

• Overview: SOPHiA GENETICS, a cloud-native healthcare technology company and global leader in data-driven medicine, announced a strategic collaboration with Microsoft and NVIDIA.

• Objective: To develop a streamlined and scalable Whole Genome Sequencing (WGS) analytical solution for healthcare institutions.

• Key Details:

  • The solution integrates SOPHiA GENETICS’ genomics expertise with Microsoft’s cloud infrastructure and NVIDIA’s AI technologies.

  • Expected to be available to clients by the end of 2024.

  • Enables scientists and physicians to access fully annotated whole genome insights rapidly — often within the same day.

• Impact: Aims to accelerate genomic analysis and empower data-driven clinical decision-making in healthcare.

Recent Developments in the Consumer Genomics Market

• In April 2025, the expansion of cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow was announced by the Frankfurt Prime Standard: QIA. It included the resolutions for lentivirus-based applications that are used in the manufacturing of advanced treatments like chimeric antigen receptor T-cell (CAR-T), which is a personalized form of cancer immunotherapy.
• In March 2025, a new kit, which is an indigenous open-system RT-PCR (Reverse Transcription Polymerase Chain Reaction) that will make tuberculosis diagnosis simple, rapid, and 5 times more cost-effective, was developed. The kit was developed by Huwel Lifesciences and is known as Quantiplus MTB FAST Detection Kit; it eliminates the DNA extraction step, which is one of the most complex steps in diagnosis. It was further approved by the Central Drugs Standard Control Organisation (CDSCO) and the Indian Council of Medical Research (ICMR).
• In July 2024, the inventor of innovative and extremely distinctive single-cell technology, Fluent BioSciences, was bought by Illumina, Inc., a leading company in the world of array-based technologies and DNA sequencing as today. The acquisition of Fluent BioSciences by Illumina will expand our multi-omics growth plan and offer customers substantial and novel capabilities in a critical growth area.
• In April 2023, the purpose of Function Oncology, a precision medicine startup, is to create a personalized functional genomics platform driven by CRISPR that will transform the landscape of targeted cancer treatment in the future. The San Diego-based firm is dedicated to developing the next generation of targeted cancer medicines by evaluating gene function at the individual patient level, as opposed to depending on conventional gene sequencing.
• In June 2023, Nutrigenomics is the latest venture of Xcode Life. The business has introduced a thorough Gene Nutrition test that addresses about 50 facets of diet. The examination examines how the macronutrients (carbs, protein, and fats) are broken down based on genotype, the likelihood of vitamin and mineral deficiencies, eating habits, managing weight in relation to nutrition, taste preferences, diet responses, and food sensitivity. Xcode investigates the relationship between food and how it impacts gene expression and health, as well as the influence of genes on an individual's body's reaction to food, as part of its focus on nutrigenomics. It adds credibility and personalization to dietary recommendations by considering each person's own genetic composition.
• In October 2022, ChemoCentryx, Inc., a biopharmaceutical company focused on oral therapies for the treatment of cancer, inflammatory illnesses, and autoimmune diseases, was acquired by Amgen for $52 per share in cash, which amounted to an estimated $3.7 billion in total merger consideration. The acquisition was successfully completed, as previously announced.

Collaborate with our experts to explore the Consumer Genomics Market at sales@towardshealthcare.com